Resultados oncológicos y funcionales de la prostatectomía radical abierta como tratamiento del cáncer de próstata en una cohorte de 1420 pacientes en la Ciudad de México

Aarón Torres-García; Rodrigo Alvarado-Larraguivel; Christian Omar González-Téllez; Manuel Alejandro Paredes-Hernández; Víctor David Ruíz-Colín; Aldo Fernández de Lara-Escalante

doi:10.48193/revistamexicanadeurologa.v81i3.723

Authors

Aarón Torres-García The American British Cowdray Medical Center, I.A.P., Ciudad de México, México. https://orcid.org/0000-0003-4473-5829
Rodrigo Alvarado-Larraguivel The American British Cowdray Medical Center, I.A.P., Ciudad de México, México. https://orcid.org/0000-0001-5586-4920
Christian Omar González-Téllez The American British Cowdray Medical Center, I.A.P., Ciudad de México, México. https://orcid.org/0000-0002-2528-3364
Manuel Alejandro Paredes-Hernández The American British Cowdray Medical Center, I.A.P., Ciudad de México, México. https://orcid.org/0000-0002-5884-4391
Víctor David Ruíz-Colín The American British Cowdray Medical Center, I.A.P., Ciudad de México, México. https://orcid.org/0000-0002-6099-3396
Aldo Fernández de Lara-Escalante The American British Cowdray Medical Center, I.A.P., Ciudad de México, México. https://orcid.org/0000-0001-5863-4960

DOI:

https://doi.org/10.48193/revistamexicanadeurologa.v81i3.723

Keywords:

Open prostatectomy, oncological outcomes, functional results

Abstract

Open radical prostatectomy, since the beginning of the last century has been the gold standard in the localized prostate cancer treatment, and the platform from which minimally invasive procedures such as laparoscopy and robot-assisted surgery have reproduced its results.

Objective: To evaluate the oncological outcomes and functional results of open radical prostatectomy in a cohort of 1420 patients in Mexico City.

Material and methods: A retrospective cohort study of 1420 cases of patients with prostate cancer undergoing radical surgery for a single surgeon (ATG) in private care hospitals.

Results: The median surveillance was 132 months (range 1 to 180 months). Cancer- specific survival was 95% (95% CI 96 to 9), 90% (95% CI 9 to 9), 7% (95%

CI 6 to 9), % (95% CI to 6) and 0% (95% CI 79), at 5, 10 and 15 years respectively. The time free of biochemical progression decreased with greater the risk group, Gleason grade and extraprostatic extension at surgery time.

Conclusion: Radical prostatectomy is up to now a procedure that offers cancer-specific survival as well as survival free of biochemical progression adequate to achieve adequate control of prostate neoplasia.

References

Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917. doi: 10.1002/ijc.25516

Malvezzi M, Bosetti C, Chatenoud L, Rodríguez T, Levi F, Negri E, et al. Trends in cancer mortality in Mexico, 1970-1999. Ann Oncol. 2004;15(11):1712–8. doi: 10.1093/annonc/mdh424

Dirección General de Información en Salud. Defunciones (Mortalidad) Cubos dinámicos. México; 2020. http://www.dgis.salud.gob.mx/contenidos/basesdedatos/bdc_defunciones_gobmx.html

Sánchez-Barriga JJ. Tendencias de mortalidad y años potenciales de vida perdidos por cáncer de próstata en los 32 estados y en las 7 regiones socioeconómicas de México en el periodo 2000-2010. Gac Med Mex. 2013;149(5):576–85.

Young HH. The early diagnosis and radical cure of carcinoma of the prostate. Being a study of 40 cases and presentation of a radical operation which was carried out in four cases. 1905. J Urol. 2002;168(3):914–21. doi: 10.1016/s0022-5347(05)64542-9

Millin T. Retropubic prostatectomy; a new extravesical technique; report of 20 cases. Lancet. 1945;2(6380):693–6. doi: 10.1016/s0140-6736(45)91030-0

Walsh PC, Lepor H, Eggleston JC. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate. 1983;4(5):473–85. doi: 10.1002/pros.2990040506

Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol. 2001;165(4):1146–51.

Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822–30. doi: 10.1016/s0090-4295(97)00238-0

Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96. doi: 10.1097/SLA.0b013e3181b13ca2

Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S. The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. J Urol. 2012;188(6):2219–24. doi: 10.1016/j.juro.2012.08.028

Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ, Yossepowitch O, Vickers AJ, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol. 2009;27(26):4300–5. doi: 10.1200/JCO.2008.18.2501

Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 1994;152(5 Pt 2):1850–7. doi: 10.1016/s0022-5347(17)32399-6

Lau WK, Blute ML, Bostwick DG, Weaver AL, Sebo TJ, Zincke H. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. J Urol. 2001;166(5):1692–7.

Kotb AF, Elabbady AA. Prognostic factors for the development of biochemical recurrence after radical prostatectomy. Prostate Cancer. 2011; 2011:485189. doi: 10.1155/2011/485189

Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML. Mayo Clinic validation of the D’amico risk group classification for predicting survival following radical prostatectomy. J Urol. 2008;179(4):1354–60; discussion 1360-1361. doi: 10.1016/j.juro.2007.11.061

Dorin RP, Daneshmand S, Lassoff MA, Cai J, Skinner DG, Lieskovsky G. Long-term outcomes of open radical retropubic prostatectomy for clinically localized prostate cancer in the prostate-specific antigen era. Urology. 2012;79(3):626–31. doi: 10.1016/j.urology.2011.09.051

Suardi N, Porter CR, Reuther AM, Walz J, Kodama K, Gibbons RP, et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer. 2008 Mar 15;112(6):1254–63. doi: 10.1002/cncr.23293

Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002;167(2 Pt 1):528–34. doi: 10.1097/00005392-200202000-00018

Roehl KA, Han M, Ramos CG, Antenor JAV, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172(3):910–4. doi: 10.1097/01.ju.0000134888.22332.bb

Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001;28(3):555–65. doi: 10.1016/s0094-0143(05)70163-4

Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011;185(3):869–75. doi: 10.1016/j.juro.2010.10.057

Oncologic and functional results of open radical prostatectomy as treatment of prostate cancer in a cohort of 1420 patients in Mexico City

Authors

DOI:

Keywords:

Abstract

References

Downloads

Published

Issue

Section

issn

Keywords

Language

Make a Submission

sociedad

Information

rmu

redessociales

Latest publications

Licencia